$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

$enta Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000119312514305189 Filed on August 12, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$2.637M	$42.05M	$1.649M
YoY Change	95.48%	2450.09%	-35.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.760M	$2.600M	$1.790M
YoY Change	57.71%	45.25%	55.65%
% of Gross Profit
Research & Development	$5.200M	$4.553M	$4.039M
YoY Change	20.93%	12.73%	-17.99%
% of Gross Profit
Depreciation & Amortization	$110.0K	$90.00K	$60.00K
YoY Change	57.14%	50.0%	100.0%
% of Gross Profit
Operating Expenses	$7.960M	$4.553M	$4.039M
YoY Change	31.57%	12.73%	-17.99%
Operating Profit		$34.90M	-$4.178M
YoY Change		-935.21%	18.42%
Interest Expense	$240.0K	$5.000K	$7.000K
YoY Change	-7.69%	-28.57%	-76.67%
% of Operating Profit		0.01%
Other Income/Expense, Net	$236.0K	$36.00K	$40.00K
YoY Change	-8.53%	-10.0%	48.15%
Pretax Income	-$5.090M	$34.93M	-$4.138M
YoY Change	14.64%	-944.15%	18.23%
Income Tax	$48.00K	$15.12M	$0.00
% Of Pretax Income		43.29%
Net Earnings	-$5.042M	$50.05M	-$4.138M
YoY Change	13.48%	-1309.59%	18.19%
Net Earnings / Revenue	-191.2%	119.03%	-250.94%
Basic Earnings Per Share	-$0.27	$2.70	-$0.23
Diluted Earnings Per Share	-$0.27	$2.61	-$0.23
COMMON SHARES
Basic Shares Outstanding	18.58M shares	18.53M shares	17.82M shares
Diluted Shares Outstanding		19.20M shares	17.82M shares

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.80M	$95.90M	$94.50M
YoY Change	-10.54%	1.48%	101.92%
Cash & Equivalents	$30.70M	$26.37M	$18.88M
Short-Term Investments	$60.10M	$69.50M	$75.70M
Other Short-Term Assets	$12.70M	$13.20M	$1.500M
YoY Change	693.75%	780.0%	200.0%
Inventory
Prepaid Expenses
Receivables	$1.724M	$399.0K	$876.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$108.0M	$111.7M	$97.87M
YoY Change	3.12%	14.11%	92.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.803M	$1.551M	$1.152M
YoY Change	60.84%	34.64%	130.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$41.00M	$41.70M	$20.20M
YoY Change	283.18%	106.44%	1088.24%
Other Assets	$4.600M	$4.600M	$400.0K
YoY Change	1050.0%	1050.0%	-69.23%
Total Long-Term Assets	$47.44M	$47.84M	$21.81M
YoY Change	286.95%	119.38%	523.0%
TOTAL ASSETS
Total Short-Term Assets	$108.0M	$111.7M	$97.87M
Total Long-Term Assets	$47.44M	$47.84M	$21.81M
Total Assets	$155.4M	$159.5M	$119.7M
YoY Change	32.86%	33.29%	120.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.874M	$1.284M	$918.0K
YoY Change	26.54%	39.87%	14.75%
Accrued Expenses	$2.872M	$2.984M	$2.023M
YoY Change	-5.37%	47.5%	-34.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.746M	$4.268M	$2.941M
YoY Change	4.86%	45.12%	-24.59%
LONG-TERM LIABILITIES
Long-Term Debt	$200.0K	$200.0K	$0.00
YoY Change
Other Long-Term Liabilities	$229.0K	$405.0K	$535.0K
YoY Change	-36.21%	-24.3%	-80.19%
Total Long-Term Liabilities	$229.0K	$405.0K	$535.0K
YoY Change	-36.21%	-24.3%	-80.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.746M	$4.268M	$2.941M
Total Long-Term Liabilities	$229.0K	$405.0K	$535.0K
Total Liabilities	$6.761M	$6.561M	$5.260M
YoY Change	3.94%	24.73%	-20.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$73.01M	-$67.97M	-$103.0M
YoY Change	-32.05%	-34.01%
Common Stock	$221.8M	$188.0K	$180.0K
YoY Change	122423.76%	4.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.000K	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Treasury Stock Shares	208.8K shares	208.8K shares	208.8K shares
Shareholders Equity	$148.7M	$153.0M	$114.4M
YoY Change
Total Liabilities & Shareholders Equity	$155.4M	$159.5M	$119.7M
YoY Change	32.86%	33.29%	120.39%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$5.042M	$50.05M	-$4.138M
YoY Change	13.48%	-1309.59%	18.19%
Depreciation, Depletion And Amortization	$110.0K	$90.00K	$60.00K
YoY Change	57.14%	50.0%	100.0%
Cash From Operating Activities	-$4.930M	$35.11M	-$5.920M
YoY Change	96.41%	-693.07%	54.97%
INVESTING ACTIVITIES
Capital Expenditures	-$490.0K	-$370.0K	-$50.00K
YoY Change	133.33%	640.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$9.700M	-$26.93M	-$48.16M
YoY Change	-230.38%	-44.08%	275.08%
Cash From Investing Activities	$9.220M	-$27.32M	-$48.22M
YoY Change	-220.68%	-43.34%	274.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	40.00K	470.0K	-1.440M
YoY Change	-66.67%	-132.64%	4700.0%
NET CHANGE
Cash From Operating Activities	-4.930M	35.11M	-5.920M
Cash From Investing Activities	9.220M	-27.32M	-48.22M
Cash From Financing Activities	40.00K	470.0K	-1.440M
Net Change In Cash	4.330M	8.260M	-55.58M
YoY Change	-143.17%	-114.86%	232.22%
FREE CASH FLOW
Cash From Operating Activities	-$4.930M	$35.11M	-$5.920M
Capital Expenditures	-$490.0K	-$370.0K	-$50.00K
Free Cash Flow	-$4.440M	$35.48M	-$5.870M
YoY Change	93.04%	-704.43%	55.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18582628	shares
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10511000
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18878000
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17929781	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18138597	shares
CY2013Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	185614	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.15
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1583031	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	208816	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3035000
CY2013Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	240000
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	260000
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217741000
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1481000
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	378000
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4526000
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1041000
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	359000
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	110468000
CY2013Q3	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	127000
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107450000
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10000
CY2013Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	989000
CY2013Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1620000
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	181000
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116973000
CY2013Q3	us-gaap	Liabilities Liabilities	6505000
CY2013Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	48000
CY2013Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1620000
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1620000
CY2013Q3	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	184000
CY2013Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	92621000
CY2013Q3	us-gaap	Assets Current AssetsCurrent	104713000
CY2013Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	103326000
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	436000
CY2013Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	10703000
CY2013Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	7517000
CY2013Q3	us-gaap	Assets Assets	116973000
CY2013Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	110841000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8859000
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	808000
CY2013Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	103324000
CY2013Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	784000
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1641000
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28133000
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2000
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1121000
CY2013Q3	enta	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	26000
CY2013Q3	enta	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	24000
CY2013Q3	enta	Accrued Preclinical And Clinical Expenses Current AccruedPreclinicalAndClinicalExpensesCurrent	127000
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18580720	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	676867	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18789536	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.21
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1405854	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.20
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1221172	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.42
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	208816	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2984000
CY2014Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	247000
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	348000
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	220741000
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1284000
CY2014Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	336000
CY2014Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22892000
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4268000
CY2014Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	436000
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	953000
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	405000
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	152953000
CY2014Q2	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	190000
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67970000
CY2014Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	477000
CY2014Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1675000
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	188000
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	159514000
CY2014Q2	us-gaap	Liabilities Liabilities	6561000
CY2014Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	68000
CY2014Q2	us-gaap	Recorded Unconditional Purchase Obligation RecordedUnconditionalPurchaseObligation	437000
CY2014Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1888000
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1675000
CY2014Q2	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	147000
CY2014Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	69513000
CY2014Q2	us-gaap	Assets Current AssetsCurrent	111678000
CY2014Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	111217000
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	436000
CY2014Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	41700000
CY2014Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	11183000
CY2014Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	21972000
CY2014Q2	us-gaap	Assets Assets	159514000
CY2014Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	133185000
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	34028000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26374000
CY2014Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	4149000
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	399000
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24960000
CY2014Q2	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7559000
CY2014Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	111213000
CY2014Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	2259000
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1950000
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	38818000
CY2014Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	41700000
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9067000
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2000
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1551000
CY2014Q2	enta	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	48000
CY2014Q2	enta	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	44000
CY2014Q2	enta	Accrued Preclinical And Clinical Expenses Current AccruedPreclinicalAndClinicalExpensesCurrent	623000
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0103	pure
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7052989	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.73	pure
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M2D
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	148000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8367000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2454000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-61578000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1288000
	us-gaap	Share Based Compensation ShareBasedCompensation	777000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	16974000
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2526000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	13156000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7052989	shares
	us-gaap	Revenues Revenues	30704000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	291000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	13966000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14070000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	100253000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2126000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	146000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-22000
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	217000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2126000
	us-gaap	Operating Income Loss OperatingIncomeLoss	13730000
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-912000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	100000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3540000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-173000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	340000
	us-gaap	Net Income Loss NetIncomeLoss	14070000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-697000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-104000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	404000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-104000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4433000
	us-gaap	Paid In Kind Interest PaidInKindInterest	23000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	56789000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	161808000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-17000
	us-gaap	Interest Expense InterestExpense	23000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-620000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	37000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	59892000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12541000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	437000
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	13670000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	711000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	36625000
	enta	Undistributed Earnings Allocated To Participating Securities Diluted UndistributedEarningsAllocatedToParticipatingSecuritiesDiluted	13670000
	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	1170000
	dei	Entity Registrant Name EntityRegistrantName	ENANTA PHARMACEUTICALS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001177648
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0189	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	465	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19168368	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	892537	shares
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	483570	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.8070	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y22D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.56
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18275831	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	29.73
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	25111000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y2M12D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	650939	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	9343	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, management’s judgments of separate units of accounting and best estimate of selling price of those units of accounting within its revenue arrangements; the valuation of common stock for the periods prior to the completion of the Company’s initial public offering (“IPO”), valuation of warrants, Series 1 nonconvertible preferred stock and stock-based awards; the useful lives of property and equipment; and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</p> </div>
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15228000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10000
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment
	us-gaap	Share Based Compensation ShareBasedCompensation	1887000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	20793000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	242000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	17515000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7413000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8716000
	us-gaap	Revenues Revenues	45104000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-161000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	39478000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	24358000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	85750000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	39480000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	329000
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-268000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	39480000
	us-gaap	Operating Income Loss OperatingIncomeLoss	24311000
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1475000
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15333000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-409000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	47000
	us-gaap	Net Income Loss NetIncomeLoss	39480000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1636000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	543000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7255000
	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	-105000
	us-gaap	Maintenance Costs MaintenanceCosts	105000
	us-gaap	Paid In Kind Interest PaidInKindInterest	14000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1120000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-200000
	us-gaap	Interest Expense InterestExpense	14000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-190000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	46000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13538000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1015000
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	105000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	711000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	70164000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15122000
	enta	Office Leases Expire OfficeLeasesExpire	September 2018
	enta	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	5000000
	enta	Onetime License Costs OnetimeLicenseCosts	50000
	enta	Undistributed Earnings Allocated To Participating Securities Diluted UndistributedEarningsAllocatedToParticipatingSecuritiesDiluted
	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	1824000
	enta	Conversion Of Warrants Into Preferred Stock ConversionOfWarrantsIntoPreferredStock	206000
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0116	pure
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17819813	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.77	pure
CY2013Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17819813	shares
CY2013Q2	us-gaap	Revenues Revenues	1649000
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4225000
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4138000
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4138000
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	64000
CY2013Q2	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-17000
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4138000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4178000
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	40000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-4138000
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-87000
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-87000
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1788000
CY2013Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	239000
CY2013Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5827000
CY2013Q2	us-gaap	Interest Expense InterestExpense	7000
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4039000
CY2013Q2	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities
CY2013Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	237000
CY2013Q2	enta	Undistributed Earnings Allocated To Participating Securities Diluted UndistributedEarningsAllocatedToParticipatingSecuritiesDiluted
CY2013Q2	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0193	pure
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.61
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19203270	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.76	pure
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	674437	shares
CY2014Q2	us-gaap	Interest Expense InterestExpense	5000
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4553000
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.70
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18528833	shares
CY2014Q2	us-gaap	Revenues Revenues	42051000
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	49988000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34931000
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	50053000
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	106000
CY2014Q2	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	40000000
CY2014Q2	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-65000
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	50053000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	34895000
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	50053000
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-65000
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-65000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2603000
CY2014Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	776000
CY2014Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7156000
CY2014Q2	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	237000
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15122000
CY2014Q2	enta	Undistributed Earnings Allocated To Participating Securities Diluted UndistributedEarningsAllocatedToParticipatingSecuritiesDiluted
CY2014Q2	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0

Files In Submission

Name	View Source	Status
0001193125-14-305189-index-headers.html	Edgar Link	pending
0001193125-14-305189-index.html	Edgar Link	pending
0001193125-14-305189.txt	Edgar Link	pending
0001193125-14-305189-xbrl.zip	Edgar Link	pending
d743226d10q.htm	Edgar Link	pending
d743226dex311.htm	Edgar Link	pending
d743226dex312.htm	Edgar Link	pending
d743226dex321.htm	Edgar Link	pending
enta-20140630.xml	Edgar Link	completed
enta-20140630.xsd	Edgar Link	pending
enta-20140630_cal.xml	Edgar Link	unprocessable
enta-20140630_def.xml	Edgar Link	unprocessable
enta-20140630_lab.xml	Edgar Link	unprocessable
enta-20140630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g743226g30c55.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

2014 Q3 Form 10-Q Financial Statement

#000119312514305189 Filed on August 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA ENANTA PHARMACEUTICALS INC Stock $enta

2014 Q3 Form 10-Q Financial Statement

#000119312514305189 Filed on August 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta